Kryxana 200mg Tablet

About Kryxana 200mg Tablet

Kryxana 200mg Tablet contains Ribociclib Succinate, a targeted anticancer medication belonging to the cyclin-dependent kinase (CDK) 4/6 inhibitor class. It is primarily used in combination with hormone therapy for the treatment of hormone receptor (HR)-positive, HER2-negative advanced, metastatic, or high-risk early-stage breast cancer in adults. Ribociclib works by blocking CDK 4 and CDK 6 enzymes, which play a key role in cancer cell growth and division, thereby slowing tumor progression and reducing the risk of cancer recurrence. Treatment with Kryxana 200mg Tablet should be initiated and supervised by an experienced oncology specialist. Patients should not take this medication if they are allergic to Ribociclib, peanuts, soya, or any of its ingredients. Before starting therapy, it is important to inform your healthcare provider about any history of liver disease, kidney disorders, heart conditions, or abnormalities affecting the QT interval, as these may require closer monitoring. Regular blood tests, liver function assessments, and electrocardiograms (ECGs) are recommended throughout treatment to ensure safety and monitor response. Pregnancy and breastfeeding should be avoided during treatment, as Ribociclib may harm an unborn baby. Effective contraception is recommended during therapy and for at least three weeks after the final dose. With appropriate monitoring and adherence to treatment, Kryxana 200mg Tablet can help improve disease control and treatment outcomes in patients with HR-positive, HER2-negative breast cancer.